Michael P. Caligiuri, Ph.D.
8950 Villa La Jolla Drive, Suite A-208
La Jolla, CA 92037
Phone #: 858-455-5050
FAX #: 858-455-9540
Dr. Caligiuri attended the University of Wisconsin, Madison where he received a Ph.D. in neuroscience with an emphasis in motor control. Upon completion of this work in 1986, he accepted a post-doc position in San Diego where he started a movement disorders laboratory for studying levodopa-induced dyskinesia in Parkinson’s disease. Dr. Caligiuri began working with faculty in the Department of Psychiatry in 1987 to test novel instruments for quantifying tardive dyskinesia and drug-induced parkinsonism. In 2006, he was appointed as Director, Human Research Protection Program at UCSD overseeing five IRBs charged with monitoring the ethical and regulatory conduct of human subjects research at UCSD.
Dr Caligiuri’s research focuses on understanding how motor function and impairment can be useful in the diagnosis and treatment of affective and psychotic illnesses. Significant research contributions include: the demonstration that early drug-induced parkinsonism can predict long-term persistent movement disorders in patients treated with antipsychotics; finding that affective state in bipolar disorder may be related to a disturbance of inhibitory regulation within the basal ganglia and that antipsychotics and or mood stabilizers normalize cortical and subcortical hyperactivity in patients with bipolar disorder; development of a portable, simple to use transducer for quantifying tremor; and demonstrating that measures of handwriting kinematics can detect subtle differences in EPS liability between various antipsychotic medications. His current research aims to understand the effects of drugs, disease, and aging on handwriting kinematics to enable the forensic community to better understand these contributions when authenticating signatures.
Dr. Caligiuri’s clinical focus is on movement disorders with particular emphasis of differentiating idiopathic or degenerative disorders from medication-induced disorders and developing technologies for the rapid quantification of extrapyramidal motor signs such as tremor, dyskinesia and bradykinesia.
Caligiuri MP, Lohr JB, Jeste DV (1993) Parkinsonism in neuroleptic-naive schizophrenic patients Am J Psychiat 150:1343-1348
Caligiuri MP, Lacro JP, Jeste DV (1999) Incidence and predictors of drug-inducedparkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 19: 322-328
Caligiuri MP, Brown GG, Meloy MJ, Eberson SC, Kindermann SS, Frank LR, Eyler Zorrilla L, Lohr JB (2003). An fMRI study of affective state and medication on cortical and subcortical brain regions during motor performance in bipolar disorder. Psychiatry Research: Neuroimaging 123: 171-182.
Caligiuri MP, Tripp MP (2004) A portable hand-held device for quantifying and standardizing tremor assessment. J Medical Engineering and Technology 28(6):254-62.
Caligiuri MP and Buitenhuys C. (2005) Do Preclinical Findings of Methamphetamine-Induced Motor Abnormalities Translate to an Observable Clinical Phenotype? Neuropsychopharmacology 30: 2125-2134
Caligiuri MP, Brown GG, Meloy MJ, Eberson S, Niculescu AB, Lohr JB (2006) Striatopallidal regulation of affect in bipolar disorder. J Affect Disord. 91(2-3):235-42.
Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, Harricharan R. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008 Feb;28(1):69-73.
Caligiuri MP, Teulings HL, Dean CE, Niculescu AB, Lohr JB (2010) Handwriting movement kinematics for quantifying EPS in patients treated with atypical antipsychotics. Psychiatry Research 177: 77-83